Advertisement · 728 × 90

Posts by Lillemeier lab

Post image

Deadline approaching! The CiM-IMPRS #PhD program in #Münster is recruiting: 16 #PhD positions in Life & Natural Sciences. Great chance to do cutting-edge research in a vivid international environment—apply by May 1st: www.uni-muenster.de/CiM-IMPRS/ap...
@uni-muenster.de @mpi-muenster.bsky.social

4 hours ago 6 4 0 2
Preview
EFIS Webinar Landmark Discoveries - 12. May 2026, 5 pm CET | EFIS Taskforce EDUCATION Evolution of Adaptive Immunity by Prof. Thomas Boehm (Emeritus Director Max Planck Institute for Biology Tübingen)

🔬 EFIS Webinar: Landmark Discoveries in Immunology

🗓️ Date: 12 May 2026
🕔Time: 5:00 PM (CET)
🎤 Host: Vera Martins (Ulm)

👉 Register now: www.efisedu.de/event-detail...

Don’t miss this opportunity to learn from a leading expert in the field!

1 day ago 1 1 1 0

Deep mapping of structural perturbations to energetics enables precise TCR design www.biorxiv.org/content/10.64898/2026.04...

1 day ago 3 1 0 0
Preview
Improving immunotherapy in solid tumors using FMT Recent clinical trials demonstrate that fecal microbiota transplantation (FMT) enhances first-line immune checkpoint inhibitor efficacy in renal cell carcinoma, cutaneous melanoma, and non-small cell ...

Improving immunotherapy in solid tumors using FMT: Cell www.cell.com/cell/fulltex...

2 days ago 8 6 0 0

#work with us!

1 week ago 3 3 0 0
Lipid Code to Life Modern lipid biology has evolved far beyond the traditional view of lipids as simple building blocks or energy substrates. Lipids are now recognised as dynamic regulators of biological structures and…

Dear Lipid and Membrane Enthusiasts,

There is only one month!! left to register and submit your abstracts for the @embo.org Workshop “Lipid Code to Life”, which will be held from September 7–11, 2026, in Dresden, Germany.

Workshop program and registration page: meetings.embo.org/event/26-lip...

6 days ago 15 19 1 0
Post image

Join us for a 📢 #CIBSS / @sfb1381.bsky.social Joint Seminar!

🗓 21 Apr 2026 | 12:00–13:00
👉 @nikfortelny.bsky.social (@unisalzburg.bsky.social)

📍 Lecture Hall, Institute of Biology I, Hauptstr. 1

🔗More info: kurzlinks.de/c295

#SynBio #ProteinEngineering #MultiOmics

2 days ago 0 2 0 0
Advertisement

🧭 Just one day to go - April 21, 5–6 PM CET. The first of the two talks is happening tomorrow. Register here: docs.google.com/forms/d/e/1F...

#Immunology #DayOfImmunology #Tcells #ScienceSeminar
@efis-immunology.bsky.social @iuis-online.bsky.social @dgfi-yi.bsky.social @helmholtzhzi.bsky.social

2 days ago 1 2 0 0
IRB Barcelona invites applications for Group Leader positions in Chemical
Biology (one) and Structural Biology (one) as part of its strategic effort to
strengthen molecular sciences.
The successful candidates will join a highly multidisciplinary and collaborative
institute with strong expertise in cancer and metastasis, ageing and cell
reprogramming, metabolism, cell differentiation, signal transduction, and gene
expression, working at the interface of structural and computational biology,
chemistry, and biology.
IRB Barcelona is embedded in a vibrant scientific ecosystem and maintains
close collaborations with major research infrastructures such as the Barcelona
Supercomputing Center (BSC) and the ALBA Synchrotron, as well as leading
research centres, universities, and hospitals in Barcelona.

About IRB Barcelona
IRB Barcelona
(www.irbbarcelona.org)
is a multidisciplinary research
institute where scientists collaborate
to address fundamental biomedical
questions and unmet medical needs.
The Institute currently hosts more
than 500 members from around the
world across 27 research groups.
How to apply
Applications should include a CV, letter
of intent, brief (2-page) research
proposal, and the names and contact
details of at least three referees.
Applications must be submitted via
https://recruitment.irbbarcelona.org
no later than 22 May 2026, quoting
reference GL/26/01 (Chemical Biology)
or GL/26/02 (Structural Biology).
The successful candidates are expected
to join in Q4 2026 or 2027, with flexibility
depending on individual circumstances.
For Informal enquiries, please contact
the chair of the Search Committee
(Prof. Xavier Salvatella, at
xavier.salvatella@irbbarcelona.org)
and for details and updates on
the selection process please
contact the Head of People at
(irbglcall@irbbarcelona.org)

IRB Barcelona invites applications for Group Leader positions in Chemical Biology (one) and Structural Biology (one) as part of its strategic effort to strengthen molecular sciences. The successful candidates will join a highly multidisciplinary and collaborative institute with strong expertise in cancer and metastasis, ageing and cell reprogramming, metabolism, cell differentiation, signal transduction, and gene expression, working at the interface of structural and computational biology, chemistry, and biology. IRB Barcelona is embedded in a vibrant scientific ecosystem and maintains close collaborations with major research infrastructures such as the Barcelona Supercomputing Center (BSC) and the ALBA Synchrotron, as well as leading research centres, universities, and hospitals in Barcelona. About IRB Barcelona IRB Barcelona (www.irbbarcelona.org) is a multidisciplinary research institute where scientists collaborate to address fundamental biomedical questions and unmet medical needs. The Institute currently hosts more than 500 members from around the world across 27 research groups. How to apply Applications should include a CV, letter of intent, brief (2-page) research proposal, and the names and contact details of at least three referees. Applications must be submitted via https://recruitment.irbbarcelona.org no later than 22 May 2026, quoting reference GL/26/01 (Chemical Biology) or GL/26/02 (Structural Biology). The successful candidates are expected to join in Q4 2026 or 2027, with flexibility depending on individual circumstances. For Informal enquiries, please contact the chair of the Search Committee (Prof. Xavier Salvatella, at xavier.salvatella@irbbarcelona.org) and for details and updates on the selection process please contact the Head of People at (irbglcall@irbbarcelona.org)

Was just asked to spread the word about this position.
Structural biology and Chemical Biology positions in Barcelona, one of the great cities of the world!
www.irbbarcelona.org/sites/defaul...

3 days ago 15 20 0 0
Video

It all started with (#2 in the series)
New in Nature Methods - spontaneously blinking dyes for live cell super-resolution. No harsh chemicals or damaging light.
2 Nature family papers in two weeks 🤯
@rhodamine110.bsky.social @sciencethecat.bsky.social
doi.org/10.1038/s415... doi.org/10.1038/s414...

4 days ago 6 3 1 0
Post image

Bringing Natural killer cells to the clinic: opportunities beyond #cancer. Review from Marjorie Cayatte, Valentin Picant, Marie Vétizou, and Eric Vivier: rupress.org/jem/article/...

📘 Part of JEM #Immunology collection 👉 rupress.org/jem/collecti...

#AAI2026

4 days ago 5 2 0 0

Gene delivery of immunomodulatory cytokines to the lung preserves respiratory function during inflammatory challenge @labliston.bsky.social @sciimmunology.bsky.social
@babrahaminst.bsky.social @drntombizodwa.bsky.social
www.science.org/doi/10.1126/...

5 days ago 18 5 0 0
Post image

What does it take to truly understand #cancer in all of its complexity?

Delighted to share our Review in Cell "Cancer ecosystems: A dynamic interplay across scales" with Daniela Quail, where we propose a multi-scale framework connecting tumor ecology with physiology 🧪⚕️

www.cell.com/cell/fulltex...

6 days ago 68 32 7 0
Preview
CD20 tails interact with the 14-3-3/GEF-H1 complex and microtubule network upon PKCδ phosphorylation - The EMBO Journal CD20 is a four-helix transmembrane protein specifically expressed in B-cells that serves as a prominent target of therapeutic anti-CD20 antibodies. It is localized in a membrane nanocluster harboring ...

CD20 tails interact with the 14-3-3/GEF-H1 complex and microtubule network upon PKCδ phosphorylation
Kathrin Kläsener, Michael Reth and collaborators
link.springer.com/article/10.1...

5 days ago 5 3 0 0
Preview
Overcoming functional and translational challenges of cellular immunotherapies for solid tumors Though successful in hematologic cancers, cell therapies face major barriers in solid tumors. Chen et al. review functional and translational obstacles undermining autologous and allogeneic cell-based therapies for solid tumors. They assess key impediments, contributing factors, and emerging solutions, emphasizing engineering advances and new technologies to enable next-generation cellular immunotherapies.

Overcoming functional and translational challenges of cellular immunotherapies for solid tumors

6 days ago 5 3 0 0
Post image

Just out: A series of spontaneously blinking dyes for super-resolution microscopy
with @rhodamine110.bsky.social and an incredible team of collaborators.
www.nature.com/articles/s41...

It's been an amazing few weeks -- this follows our cytoplasmic tradewinds paper.
www.nature.com/articles/s41...

5 days ago 10 3 0 0
Post image

‼️Don't miss the next Immunity & Infection #seminar on Monday, April27, 2026 with Prof. Dr. Werner Held
@sfb1160.bsky.social

5 days ago 0 1 0 0
Advertisement
Am 30.4. um 17 Uhr findet unser Webinar mit Prof. Carolin Daniel (Helmholtz Zentrum, München) und Prof. Matthias Edinger (Universitätsklinikum, Regensburg) statt.

Das Webinar startet mit jeweils einem Impulsvortrag zu den Themen „Immunsystem und Stoffwechsel im Dialog – die zentrale Rolle der regulatorischen T-Zellen“ und „Immunregulation in der allogenen Stammzelltransplantation“. Danach besteht Raum für inhaltlichen Austausch. Bei der Online-Anmeldung ist Platz für Fragen an die Vortragenden eingerichtet. Diese sammeln wir und fassen sie zusammen. Frau Daniel und Herr Edinger werden diese Fragen und andere im Anschluss an ihren Impulsvortrag aufgreifen. Wir freuen uns darauf!

Prof. Carolin Daniel: Immunsystem und Stoffwechsel im Dialog – die zentrale Rolle der regulatorischen T-Zellen
Carolin Daniel ist Professorin für Immunmodulation an der Ludwig-Maximilians-Universität München und Direktorin des Instituts für Metabolismus und Immunologie am Helmholtz Zentrum München. Ihr Labor untersucht das Zusammenspiel von Immunsystem und Metabolismus, mit besonderem Fokus auf regulatorische T-Zellen. Sie verfolgt die Vision, diese gezielt für die präzise Manipulation des Immunsystems zu nutzen, um Autoimmunität und Stoffwechselerkrankungen wie Diabetes effektiv zu bekämpfen.


Prof. Matthias Edinger: Immunregulation in der allogenen Stammzelltransplantation 
Prof. Edinger ist Leiter des Bereichs Stammzelltransplantation & Zelltherapie am Universitätsklinikum Regensburg und Direktoriumsmitglied des Leibniz-Instituts für Immuntherapie. Professor Matthias Edinger und sein Team untersuchen immunologische Mechanismen der allogenen Stammzelltransplantation (SZT). Ziel ist es, Immunreaktionen zwischen Spenderzellen und Empfänger nach einer SZT besser zu verstehen, um die Sicherheit und Wirksamkeit dieser Behandlungsmethode zu verbessern. 


Zur Anmeldung zum Webinar: https://das-immunsystem.de/tag-der-immunologie/webinar-2026/

Am 30.4. um 17 Uhr findet unser Webinar mit Prof. Carolin Daniel (Helmholtz Zentrum, München) und Prof. Matthias Edinger (Universitätsklinikum, Regensburg) statt. Das Webinar startet mit jeweils einem Impulsvortrag zu den Themen „Immunsystem und Stoffwechsel im Dialog – die zentrale Rolle der regulatorischen T-Zellen“ und „Immunregulation in der allogenen Stammzelltransplantation“. Danach besteht Raum für inhaltlichen Austausch. Bei der Online-Anmeldung ist Platz für Fragen an die Vortragenden eingerichtet. Diese sammeln wir und fassen sie zusammen. Frau Daniel und Herr Edinger werden diese Fragen und andere im Anschluss an ihren Impulsvortrag aufgreifen. Wir freuen uns darauf! Prof. Carolin Daniel: Immunsystem und Stoffwechsel im Dialog – die zentrale Rolle der regulatorischen T-Zellen Carolin Daniel ist Professorin für Immunmodulation an der Ludwig-Maximilians-Universität München und Direktorin des Instituts für Metabolismus und Immunologie am Helmholtz Zentrum München. Ihr Labor untersucht das Zusammenspiel von Immunsystem und Metabolismus, mit besonderem Fokus auf regulatorische T-Zellen. Sie verfolgt die Vision, diese gezielt für die präzise Manipulation des Immunsystems zu nutzen, um Autoimmunität und Stoffwechselerkrankungen wie Diabetes effektiv zu bekämpfen. Prof. Matthias Edinger: Immunregulation in der allogenen Stammzelltransplantation Prof. Edinger ist Leiter des Bereichs Stammzelltransplantation & Zelltherapie am Universitätsklinikum Regensburg und Direktoriumsmitglied des Leibniz-Instituts für Immuntherapie. Professor Matthias Edinger und sein Team untersuchen immunologische Mechanismen der allogenen Stammzelltransplantation (SZT). Ziel ist es, Immunreaktionen zwischen Spenderzellen und Empfänger nach einer SZT besser zu verstehen, um die Sicherheit und Wirksamkeit dieser Behandlungsmethode zu verbessern. Zur Anmeldung zum Webinar: https://das-immunsystem.de/tag-der-immunologie/webinar-2026/

Für Interessierte an immunologischen Themen haben wir rund um den Tag der Immunologie ein Webinar organisiert - zur Anmeldung: das-immunsystem.de/tag-der-immu...
🙂 Wir freuen uns über Ihr Weitersagen und Weiterleiten ...
#Immunology #DayOfImmunology #Immunologie
@dgfi-yi.bsky.social

6 days ago 1 3 0 0
Post image

@biorxivpreprint.bsky.social @emoryuniversity.bsky.social
Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T cell responses during chronic viral infection
www.biorxiv.org/content/10.6...

6 days ago 3 2 1 0
Preview
A series of spontaneously blinking dyes for super-resolution microscopy - Nature Methods A series of spontaneously blinking dyes in the far-red range facilitate single-molecule localization microscopy. These dyes vary in their blinking properties and can be matched to the applications and...

Out in @natmethods.nature.com: More dyes. They work. Quite well. And blink. Pick the one that fits your target, your technique, and your labeling density. With too many collaborators and institutes to list, but anchored at @hhmijanelia.bsky.social www.nature.com/articles/s41...

1 week ago 166 64 2 2
Post image

New Journal for ImmunoTherapy of Cancer review: "Bright side of the dark genome: antigens for next-gen cancer vaccines" jitc.bmj.com/content/14/4...

@bernardafox.bsky.social

1 week ago 1 1 0 0

🚨New publication from @kraftlabfr.bsky.social!

1 week ago 1 1 0 0

We are looking for an experienced light microscopy specialist, motivated to support our users in the Advanced Light Microscopy Facility at EMBL Heidelberg.
embl.wd103.myworkdayjobs.com/en-US/EMBL/j... -closing date 11 May 2026 @eurobioimaging.bsky.social @globalbioimaging.bsky.social

1 week ago 35 35 0 2
Post image

#JobAlert

We’re looking for a #ScienceCommunication Officer (parental leave coverage) with creativity, a strong feel for language and media, and curiosity for emerging topics.

🗓️ Apply by 24 April 2026
👉 More info: kurzlinks.de/6qoo

Fixed-term until 27 November 2026.

#UniversityOfFreiburg

1 week ago 5 10 0 1
Advertisement

#lipidtime!

1 week ago 17 6 1 0
Post image

Join us for an exciting talk by Tristan Wagner this Thursday, April 16!

1 week ago 1 1 0 0
Post image

New pre-print from the lab! We show that the subtilase SBT12a is essential for symbiosome stabilization in Medicago. Using HUNTER proteomics, we even got some of its substrates. Have a look.
www.biorxiv.org/content/10.6...

1 week ago 55 34 3 3
Video

Salk scientist Shrek Chalasani has been awarded up to $41.3M from ARPA-H to advance sonogenetics—using ultrasound to precisely control cells in the body.

The goal: potential noninvasive treatments for conditions like peripheral neuropathies.

Learn more: www.salk.edu/news-release...

1 week ago 6 4 0 0

Looking for a course on STED? You still have time to apply by 17 April 🔬⏰ @gerbi-gmb.de @eurobioimaging.bsky.social @eulimi.bsky.social @globalbioimaging.bsky.social @france-bioimaging.bsky.social @bioimaginguk.bsky.social @danishbioimaging.bsky.social @bioimagingna.bsky.social

2 weeks ago 10 7 0 0
Post image

Lymph node T cells bound by checkpoint blockade anti-PD-1 antibdoies share TCR clonotypes with intratumoral exhausted CD8+ T, suggesting their migration to tumor sites after treatment
www.nature.com/articles/s41...
@natcomms.nature.com

1 week ago 3 2 0 0